Recently, two new drugs have been approved in metastatic GIST, namely ripretinib after failure of at least three lines, including imatinib [9], and avapritinib in GIST with the PDGFRA exon 18 D842V mutation [10]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.